RIP140 and LCoR expression in gastrointestinal cancers
Metrics: PDF 475 views | HTML 1125 views | ?
Mouna Triki1,2, Dorra Ben Ayed-Guerfali2, Ines Saguem3, Slim Charfi3, Lobna Ayedi3, Tahia Sellami-Boudawara3, Vincent Cavailles1,* and Raja Mokdad-Gargouri2,*
1IRCM (Institute of Cancer Research of Montpellier), INSERM U1194, Montpellier University, Montpellier, France
2Center of Biotechnology of Sfax, Laboratory of Eukaryotic Molecular Biotechnology, Sfax University, Sfax, Tunisia
3Department of Anatomopathology, Habib Bourguiba Hospital, Sfax, Tunisia
*These authors have to be considered as last co-authors
Vincent Cavailles, email: firstname.lastname@example.org
Keywords: gastrointestinal cancer; RIP140; LCoR; immunohistochemistry; patient survival
Received: September 04, 2017 Accepted: November 05, 2017 Published: November 25, 2017
The transcription coregulators RIP140 and LCoR are part of a same complex which controls the activity of various transcription factors and cancer cell proliferation. In this study, we have investigated the expression of these two genes in human colorectal and gastric cancers by immunohistochemistry. In both types of tumors, the levels of RIP140 and LCoR appeared highly correlated. Their expression tended to decrease in colorectal cancer as compared to adjacent normal tissues but was found higher in gastric cancer as compared to normal stomach. RIP140 and LCoR expression correlated with TNM and tumor differentiation. Significant correlations were observed with expression levels of key proteins involved in tumor progression and invasion namely E-cadherin and Cyclooxygenase-2. Survival analysis showed that patients with LCoRlow/RIP140high colorectal tumors have a significant prolonged overall and disease-free survival. In gastric cancer, high LCoR expression was identified as an independent marker of poor prognosis suggesting a key role in this malignancy. Altogether, these results demonstrate that RIP140 and LCoR have a prognostic relevance in gastrointestinal cancers and could represent new potential biomarkers in these tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.